Market Assessment
2019 is seen as the year of NASH in the biotech industry. The recent top-line data readout for Phase 3 investigative drug candidates, selonsertib by Gilead (GILD) and obeticholic acid by Intercept (ICPT), further demonstrated the complexity of NASH and the clinical changes being encountered by biopharmas in developing effective therapeutics for NASH-related diseases. The spotlight this week belongs to CymaBay (CBAY) and Viking (VKTX). CymaBay recently announced the completion of patient enrollment for seladelpar in Phase 2b NASH trial. The interim data readout is